Clinical Trial Update: Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the safety, tolerability, and immunogenicity of the pneumococcal vaccine VAX-31 in adults 50 and older with prior pneumococcal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• VAX-31 (31-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Vaxcyte, Inc. | Conditions: Pneumococcal Vaccines | Phase 3 | Status: RECRUITING